Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.39 CHF | -0.25% |
|
-18.16% | -18.16% |
Sales 2024 * | 46.07B 41.18B | Sales 2025 * | 46B 41.12B | Capitalization | 82.02B 73.32B |
---|---|---|---|---|---|
Net income 2024 * | -5.42B -4.84B | Net income 2025 * | 10.22B 9.14B | EV / Sales 2024 * | 2.63 x |
Net Debt 2024 * | 39.16B 35.01B | Net Debt 2025 * | 31.88B 28.5B | EV / Sales 2025 * | 2.48 x |
P/E ratio 2024 * |
-14.9
x | P/E ratio 2025 * |
7.81
x | Employees | - |
Yield 2024 * |
5.95% | Yield 2025 * |
6.24% | Free-Float | 69.27% |
Latest transcript on Bristol-Myers Squibb Company
![Extreme 44.39](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+17.90% | 228B | |
+14.86% | 177B | |
+0.45% | 164B |
- Stock Market
- Equities
- BMY Stock
- BMY Stock